Society for Biomolecular Sciences, Washington Convention & Trade Center, Seattle, Washington, USA
September 17-21, 2006
Session topics include:
> Advanced Technology for Drug Discovery
> Target Biology & Screening
> Cell & Protein Production: Keeping Pace with Drug Discovery
> Creating Chemical Space for Lead Discovery
> Defining Target & Compound Specificity
> Hit to Lead Processes
> Imaging & High Content Assays
> Structural Biology & Lead Optimization
> ADME/Toxicology in Early Drug Discovery
> Knowledge Management & Extracting Value from Large Data Sets
> Biomarkers for Preclinical & Clinical Evaluation of New Drugs
> Drug Discovery for Diseases of the Developing World
> Systems Biology & Confluence with Drug Discovery
> The theme of the SBS 2006 annual conference in Seattle highlights the impact
> of screening and technology applications on drug discovery. With over a decade
> of HTS and combinatorial chemistry strategies now behind us, it is important
> to understand and critique the impact these technologies have had on providing
> better hits, better leads and most of all, better drug candidates to
> ultimately improve the quality of patient care.
|
|
|
Invited Speakers:
|
|
Dora Akunyili, PhD
Director General
National Agency for Food and Drug Administration
and Control
NigeriaNils Daulaire, MD, PhD
President and CEO
Global Health Council
Washington, DC Sam Eletr acting CEO of Population Genetics, Ltd., Cambridge, UK, as a Director of Third Wave Technologies, of Faust Pharmaceuticals and of SpinX Technologies. Dr. Leroy Hood, co-founder of the Institute for Systems Biology in Seattle, Washington. Dr. Roger Tung,Vice President of Drug Discovery, Vertex Pharmaceuticals Incorporated, San Diego, CA.
|
|